Serotonin toxicity, also referred to as serotonin syndrome, is an adverse reaction resulting from acute, excessive serotonergic activity at serotonin receptors (notably 5‑hydroxytryptamine 1A and 2A). It typically follows initiation or dose escalation of a serotonergic medication, an overdose, or through interacting drugs that increase serotonergic transmission. The condition can be life‑threatening and requires prompt identification and management.
Presentation spans a spectrum from mild agitation to marked neuromuscular findings and autonomic instability. Key features include inducible clonus, spontaneous or ocular clonus, agitation, diaphoresis, tremor and hyperreflexia. Delirium and autonomic hyperactivity may be present in more severe cases.
Diagnosis is clinical and may be guided by the Hunter criteria, which were derived from seven variables: spontaneous clonus, inducible clonus, ocular clonus, agitation, diaphoresis, tremor and hyperreflexia. Clinicians should apply these criteria as part of an overall clinical assessment rather than relying solely on laboratory testing.
The true incidence of serotonin toxicity is not precisely known. One reported estimate is that approximately 15% of overdoses involving selective serotonin reuptake inhibitors (SSRIs) result in serotonin toxicity, and this proportion appears independent of the dose ingested. Age and sex do not materially affect risk. Importantly, coingestion of a monoamine oxidase inhibitor (MAOI) increases risk about fivefold.
Commonly implicated agents include SSRIs, tricyclic antidepressants and tramadol. Clinicians should also be aware of often‑overlooked serotonergic agents such as lithium, St. John’s wort, methadone, fentanyl and methylene blue, any of which can contribute to excessive serotonergic activity alone or in combination.
Severe hyperthermia in serotonin toxicity is a medical emergency. When excessive serotonergic stimulation produces severe muscle rigidity and impaired thermoregulation, patients can rapidly develop rhabdomyolysis, disseminated intravascular coagulation, multiorgan failure and death.
Active measures to lower body temperature are critical. Ice water immersion or other active cooling strategies should be instituted promptly. If a patient’s temperature cannot be reduced quickly to less than 39°C, escalation to paralysis and endotracheal intubation may be required to control muscle activity and allow effective cooling.
All serotonergic medications should be discontinued as soon as serotonin toxicity is suspected. Stopping the causative agents is a fundamental first step in management and may be sufficient for mild cases.
Clinicians must review the patient’s medication list thoroughly, including prescription drugs, over‑the‑counter preparations and herbal supplements, to identify potential contributors to serotonergic excess.
Supportive care is the cornerstone of management. For many patients, this includes monitoring, intravenous fluids and symptomatic treatment of autonomic instability.
Benzodiazepines are essential to reduce sympathetic outflow and control muscle hyperactivity. In moderate to severe presentations, rapid dose escalation of benzodiazepines may be required to normalize vital signs and control agitation. Intravenous fluids support hemodynamics and renal perfusion, particularly where there is concern for rhabdomyolysis.
Serotonin antagonists can be considered in moderate‑to‑severe cases as adjuncts to supportive care and benzodiazepines. Cyproheptadine is one such antagonist; it may aid clinical improvement, though the evidence base is limited and substantial initial dosing may be necessary. Other agents with serotonin‑blocking activity mentioned include chlorpromazine and olanzapine.
Because the evidence for these specific antagonists is not robust, their use is typically adjunctive and should be considered on a case‑by‑case basis in the context of overall clinical severity.
Given the potential for rapid deterioration and complex pharmacologic interactions, clinicians are advised to consult regional poison centres or medical toxicologists for guidance on diagnosis and management, dosing of specific antagonists, and escalation to advanced measures such as paralysis and intubation.
Clinicians should maintain a high index of suspicion for serotonin toxicity in patients with compatible neuromuscular and autonomic findings and a history of serotonergic medications or exposures. Early discontinuation of serotonergic agents, aggressive supportive care with benzodiazepines and active cooling for hyperthermia, and specialist consultation where needed are the key practical steps emphasized in the source guidance.